North America Type 1 Sbs If Short Bowel Syndrome With Intestinal Failure Treatment Market
Market Size in USD Million
CAGR :
% 
USD
423.58 Million
USD
709.50 Million
2025
2033
 Forecast Period |
2026 - 2033 |
 Market Size (Base Year) |
USD 423.58 Million |
 Market Size (Forecast Year) |
USD 709.50 Million |
 CAGR |
% |
| Major Markets Players |
|
North America Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Size
- The North America Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market size was valued at USD 423.58 Million in 2025 and is expected to reach USD 709.50 Million by 2033, at a CAGR of 7.3% during the forecast period. The market is witnessing steady growth due to the increasing prevalence of short bowel syndrome associated with intestinal failure, rising awareness regarding rare gastrointestinal disorders, and continuous advancements in specialized nutritional and pharmacological therapies. Growing adoption of multidisciplinary treatment approaches, coupled with improved diagnostic capabilities and enhanced patient management strategies, is further supporting market expansion.
- The increasing burden of intestinal resections resulting from conditions such as Crohn’s disease, mesenteric ischemia, trauma, congenital abnormalities, and cancer-related surgeries has significantly contributed to the demand for Type 1 SBS-IF treatments. Healthcare providers are increasingly utilizing parenteral nutrition, enteral nutrition support, and glucagon-like peptide-2 (GLP-2) analog therapies to improve intestinal adaptation, reduce complications, and enhance patient quality of life.
North America Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Analysis
- U.S. dominated the North America Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment market with the largest revenue share of 82.37% in 2025, supported by advanced healthcare infrastructure, strong reimbursement policies, and widespread access to specialized intestinal rehabilitation centers.
- The Nutritional Support Therapy segment led the market with a 41.71% share in 2025, driven by its critical role in maintaining hydration, nutrient absorption, and overall patient management during intestinal recovery.
- U.S. is expected to be the fastest-growing country at a CAGR of 7.4% from 2026 to 2033, fueled by improving healthcare accessibility, increasing awareness of rare gastrointestinal disorders, and growing investments in advanced treatment options across emerging economies.
- Emerging and Advanced Therapies are the fastest-growing treatment modality segment, projected to register a CAGR of 7.7%, reflecting increasing adoption of innovative biologics, GLP-2 analogs, and regenerative treatment approaches aimed at reducing long-term parenteral nutrition dependence.
- The Core SBS-IF Market segment dominates the market attribution category with a 56.76% revenue share in 2025, supported by the substantial patient population requiring specialized and continuous intestinal failure management.
- The Acute Phase (Type 1 SBS-IF) segment accounted for the largest share of 48.41% in 2025, driven by the immediate need for intensive nutritional support, fluid management, and clinical intervention following major intestinal resection or injury.
- The Adaptation Phase segment is anticipated to be the fastest-growing phase category, registering a CAGR of 7.6% during the forecast period, owing to increasing focus on therapies that enhance intestinal adaptation, improve nutrient absorption, and support long-term patient recovery.
Market Size & Forecast
- North America Market Value (2025): USD 423.58 Million
- Expected Market Value (2033): USD 709.50 Million
- Forecast CAGR (2026–2033): 7.3%
- Fastest Growing Country: U.S.
Report Scope and Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Segmentation
|
Attributes |
Type 1 SBS-IF treatment Key Market Insights |
|
Segments Covered |
|
|
Countries Covered |
North America · U.S. · Canada · Mexico |
|
Key Market Players |
· Takeda Pharmaceutical Company Limited (Japan) · Fresenius Kabi AG (Germany) · Baxter International Inc. (U.S.) · Nestlé Health Science (Switzerland) · Abbott Laboratories (U.S.) · Zealand Pharma A/S (Denmark) · Hanmi Pharm. Co., Ltd. (South Korea) · OxThera (Sweden) · AmeriPharma Specialty Care (U.S.) · ContinuumRx (U.S.) · Napo Therapeutics (Switzerland) · Eclipse Regenesis (U.S.) · AcuLife Healthcare Private Limited (India) · Ferring Pharmaceuticals (Switzerland) · Shandong Qidu Pharmaceutical Co., Ltd. (China) · Choice Parenteral Nutrition LLC (U.S.) · Integrated Care Systems (U.S.) · Beverly Hills Digestive Care (U.S.) · Stanford Health Care (U.S.) · Vision Parenteral (U.S.) · Amsino International, Inc. (U.S.) · Aculife Healthcare (India) · Nutrego (Netherlands) · Camvitaa (India) · Laboratoire Dielen (France) · Infusion Solutions (U.S.) · Aurora Health Care (U.S.) |
|
Market Opportunities |
· Advancements in Regenerative Medicine · Expansion of Home-Based Nutritional Care |
|
Value Added Data Infosets |
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework. |
Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market
Trends
“COMPLEX MULTIDISCIPLINARY PATIENT MANAGEMENT”
- Advancements in regenerative medicine and intestinal rehabilitation are creating strong growth opportunities for the North America Type 1 SBS-IF treatment market. Researchers and healthcare institutions are increasingly focusing on therapies that can improve intestinal adaptation, regenerate damaged intestinal tissue, and reduce long-term dependence on parenteral nutrition.
- According to studies supported by the National Institutes of Health, regenerative approaches such as stem cell therapy, tissue engineering, and intestinal transplantation research are showing promising results in improving nutrient absorption and restoring bowel function in severe SBS-IF patients.
- Several academic hospitals and specialized intestinal rehabilitation centers in North America and Europe are also expanding multidisciplinary treatment programs that combine GLP-2 therapies, advanced nutritional support, surgery, and personalized rehabilitation plans. These developments are helping improve patient survival and quality of life while opening new long-term treatment opportunities beyond traditional nutritional management.
- For instance, in February 2025, Clinical researchers from the National Institutes of Health reported that multidisciplinary intestinal rehabilitation programs combining surgeons, nutrition experts, and gastroenterologists are improving long-term survival for SBS-IF patients. Hospitals are increasingly investing in coordinated care systems to reduce costly hospital admissions.
- In conclusion, the North America Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment market is expanding due to rising SBS-IF patient cases, growing adoption of GLP-2 therapies, and increasing government support for rare disease treatments. Advances in biologic therapies, intestinal rehabilitation, and home-based care are improving patient outcomes and quality of life. However, high treatment costs, delayed diagnosis, and complex long-term patient management continue to remain major challenges for broader treatment access worldwide
Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Trends
Trend: Complex Multidisciplinary Patient Management
Advancements in regenerative medicine and intestinal rehabilitation are creating strong growth opportunities for the North America Type 1 SBS-IF treatment market. Researchers and healthcare institutions are increasingly focusing on therapies that can improve intestinal adaptation, regenerate damaged intestinal tissue, and reduce long-term dependence on parenteral nutrition. According to studies supported by the National Institutes of Health, regenerative approaches such as stem cell therapy, tissue engineering, and intestinal transplantation research are showing promising results in improving nutrient absorption and restoring bowel function in severe SBS-IF patients. Several academic hospitals and specialized intestinal rehabilitation centers in North America are also expanding multidisciplinary treatment programs that combine GLP-2 therapies, advanced nutritional support, surgery, and personalized rehabilitation plans. These developments are helping improve patient survival and quality of life while opening new long-term treatment opportunities beyond traditional nutritional management.
North America Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Dynamics
Key Market Driver: Rising SBS-If Patient Population
The rising patient population suffering from Short Bowel Syndrome with Intestinal Failure (SBS-IF) is becoming one of the major growth drivers for the North America type 1 SBS-IF treatment market. SBS-IF mainly develops when a large portion of the small intestine is removed through surgery, reducing the body’s ability to absorb nutrients and fluids properly. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the condition most commonly occurs after small bowel resection surgeries performed for diseases such as Crohn’s disease, intestinal cancers, trauma, bowel obstruction, ischemia, and congenital intestinal disorders. The growing incidence of inflammatory bowel diseases, especially Crohn’s disease, is significantly contributing to the increase in intestinal surgeries worldwide. NIDDK also states that severe Crohn’s disease patients often require repeated bowel resections, which raises the long-term risk of developing SBS-IF.
Key Restraint/Challenge: High Cost Of SBS-If Treatment
The high cost of SBS-IF treatment remains one of the biggest restraints for the North America type 1 SBS-IF treatment market. patients with short bowel syndrome with intestinal failure often require lifelong parenteral nutrition, frequent hospital monitoring, specialized intestinal rehabilitation, and advanced biologic therapies such as teduglutide. According to the U.S. Food and Drug Administration and Takeda treatment information, GLP-2 therapies like GATTEX can cost nearly USD 400,000–USD 500,000 annually per patient in the United States, making treatment financially difficult for many families and healthcare systems. In addition to drug costs, SBS-IF patients often need central venous catheter care, nutritional supplements, regular blood testing, and repeated hospital admissions due to infections or dehydration complications. These long-term medical expenses place a major burden on both patients and insurance providers, especially in countries where reimbursement coverage for rare diseases is still limited.
Key Market Opportunity: Expansion of advanced biologic and GLP-2 analog therapies.
The North America Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment market presents significant growth opportunities driven by continuous advancements in therapeutic and nutritional management approaches. Increasing adoption of innovative biologics, particularly GLP-2 analog therapies, is creating new avenues for improving intestinal adaptation and reducing dependence on parenteral nutrition. The growing focus on personalized nutrition plans and multidisciplinary care is enhancing patient outcomes and expanding treatment accessibility. Emerging economies offer substantial potential due to improving healthcare infrastructure, greater awareness of rare gastrointestinal disorders, and rising healthcare expenditure. Additionally, ongoing research in regenerative medicine, stem-cell-based therapies, and intestinal tissue engineering may transform future treatment paradigms. Expanding home-based care models and remote monitoring solutions are also expected to improve long-term disease management and patient quality of life
1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Scope
The North America Type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market is segmented into seven notable segments based on treatment modality, market attribution, disease management phase, patient type, route of administration, end user and distribution channel.
- By treatment modality
On the basis of treatment modality, the North America type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market is segmented into nutritional support therapy, pharmacological therapy, surgical & interventional treatment, and emerging & advanced therapies. In 2026, the nutritional support therapy segment is expected to dominate the market with share of 41.77% due to the critical dependence of Type 1 SBS-IF patients on nutritional rehabilitation and long-term intestinal support therapies for maintaining hydration, nutrient absorption, and overall metabolic stability
The Emerging & Advanced Therapies segment is anticipated to witness the fastest CAGR of 7.7% from 2026 to 2033, fueled by increasing research and development activities focused on innovative gastrointestinal treatments, regenerative medicine, and peptide-based therapies for short bowel syndrome with intestinal failure (SBS-IF). Growing adoption of advanced biologics, rising clinical trial investments, and the increasing demand for therapies that reduce dependence on long-term parenteral nutrition are further accelerating the growth of this segment across developed and emerging healthcare markets.
- By Market attribution
On the basis of market attribution, the North America Type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market is segmented into core SBS-IF market, SBS-IF attributable market, and adjacent/non-specific market. In 2026, the core SBS-IF market segment is expected to dominate the market with 56.75% due to the high clinical dependence on specialized nutritional therapies and targeted intestinal adaptation treatments directly associated with SBS-IF management.
The SBS-IF attributable market segment is expected to witness the fastest CAGR of 7.6% from 2026 to 2033, driven by the increasing prevalence of short bowel syndrome-associated intestinal failure and the rising demand for long-term nutritional and gastrointestinal support therapies. Growth is further supported by advancements in parenteral nutrition formulations, expanding availability of targeted therapeutics, and growing awareness regarding early diagnosis and specialized treatment approaches aimed at improving patient quality of life and reducing hospitalization rates.
- By disease management phase
On the basis of disease management phase, the North America Type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market is segmented into acute phase (Type 1 SBS-IF), adaptation phase, and recovery phase. In 2026, the acute phase (Type 1 SBS-IF) segment is expected to dominate the market with share of 48.39% due to the immediate requirement for intensive nutritional support, fluid stabilization, and hospitalization following intestinal dysfunction or surgical resection.
The adaptation phase segment is anticipated to witness the fastest CAGR of 7.6% from 2026 to 2033, driven by the increasing focus on intestinal rehabilitation therapies and advanced nutritional management strategies aimed at enhancing bowel adaptation and reducing long-term dependence on parenteral nutrition. Rising adoption of personalized treatment approaches, growing clinical awareness regarding early intervention, and continuous advancements in gastrointestinal therapeutics are further supporting the rapid growth of this segment during the forecast period.
- By patient type
On the basis of patient type, the North America type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment market is segmented into adult and pediatric. In 2026, the adult segment is expected to dominate the market with a share of 71.29% due to the higher prevalence of SBS-IF associated with Crohn’s disease, bowel resections, and gastrointestinal disorders among adults.
The pediatric segment is expected to witness the fastest CAGR of 7.6% from 2026 to 2033, driven by improving survival rates of premature infants and children with congenital intestinal disorders. Advancements in pediatric nutritional support and intestinal rehabilitation therapies are further supporting segment growth during the forecast period.
- By route of administration
On the basis of route of administration, the North America Type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market is segmented into intravenous, subcutaneous, oral, and enteral. The intravenous segment is further segmented into PN and injectables. In 2026, the intravenous segment is expected to dominate the market with share of 49.46% due to the widespread utilization of parenteral nutrition and hospital-administered therapies in critically ill SBS-IF patients with compromised intestinal absorption capacity.
The subcutaneous segment is expected to witness the fastest CAGR of 7.6% from 2026 to 2033, fueled by the increasing preference for minimally invasive drug administration methods and the growing adoption of home-based treatment solutions among patients with Type 1 SBS-IF. In addition, advancements in subcutaneous delivery formulations, improved patient convenience, reduced hospital visits, and rising demand for long-term supportive care therapies are further accelerating the growth of this segment during the forecast period.
- By end user
On the basis of end user, the North America Type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market is segmented into hospitals (acute care), home care (HPN programs), ICU settings, specialty GI centers, and pediatric specialty hospitals. In 2026, the hospitals (acute care) segment is expected to dominate the market with share of 38.56% due to the high requirement for multidisciplinary treatment management, intensive nutritional monitoring, and specialized gastrointestinal care during the acute phase of SBS-IF treatment.
The Home Care (HPN Programs) segment is expected to witness the fastest CAGR of 7.9% from 2026 to 2033, fueled by the increasing preference for home-based healthcare solutions among patients requiring long-term parenteral nutrition support. Rising healthcare costs, advancements in portable infusion technologies, and growing emphasis on improving patient comfort and quality of life are further accelerating the adoption of home parenteral nutrition (HPN) programs.
- By distribution channel
On the basis of distribution channel, the North America Type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market is segmented into hospital pharmacy, specialty pharmacy, retail pharmacy, and online pharmacy. In 2026, the hospital pharmacy segment is expected to dominate the market with share of 46.36% due to the high volume of inpatient nutritional therapies, biologics, and injectable medications administered within hospital settings for SBS-IF management.
The Specialty Pharmacy segment is expected to witness the fastest CAGR of 7.7% from 2026 to 2033, fueled by the increasing demand for personalized treatment management, home-based infusion services, and long-term nutritional support therapies for patients suffering from Type 1 SBS-IF. Additionally, the growing adoption of specialty pharmacy services for efficient drug distribution, patient monitoring, reimbursement assistance, and improved adherence to complex therapeutic regimens is further accelerating segment growth during the forecast period.
Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Regional Analysis
The U. S. Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment market Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment market is experiencing steady growth due to the increasing prevalence of short bowel syndrome with intestinal failure, rising demand for long-term parenteral nutrition therapies, and growing adoption of advanced gastrointestinal treatment solutions. The market is further supported by strong healthcare infrastructure, favorable reimbursement frameworks, and the presence of leading pharmaceutical, specialty pharmacy, and nutrition therapy providers. Increasing awareness regarding rare intestinal disorders, continuous advancements in biologic therapies and intestinal rehabilitation programs, and expanding home healthcare services are also contributing to market expansion. Additionally, ongoing research activities and rising healthcare expenditure continue to strengthen the country’s market position.
Mexico Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment market Insight
The Mexico Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment market is experiencing steady growth due to the country’s advanced healthcare infrastructure, strong focus on rare disease management, and increasing adoption of specialized nutritional support therapies. Rising prevalence of gastrointestinal disorders and growing awareness regarding intestinal failure management are driving demand for parenteral nutrition, enteral nutrition, and supportive therapeutic solutions across hospitals and home healthcare settings. In addition, favorable reimbursement policies, strong presence of pharmaceutical and medical nutrition companies, and continuous advancements in gastrointestinal care technologies are further supporting market expansion. Mexico’s well-established healthcare delivery system and increasing investment in patient-centered treatment approaches continue to strengthen market growth.
Canada Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment market Insight
The Canada Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment market is witnessing steady growth due to the country’s advanced healthcare infrastructure, rising prevalence of gastrointestinal disorders, and increasing focus on specialized nutritional therapies for intestinal failure management. The market is supported by strong adoption of parenteral nutrition, improved access to specialty pharmacy services, and growing awareness regarding early diagnosis and long-term disease management. Additionally, the presence of leading pharmaceutical companies, continuous innovation in gastrointestinal therapeutics, and favorable government healthcare policies are contributing to market expansion.
Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Share
The Type 1 SBS-IF treatment industry is primarily led by well-established companies, including:
- Takeda Pharmaceutical Company Limited (Japan)
- Fresenius Kabi AG (Germany)
- Baxter International Inc. (U.S.)
- Nestlé Health Science (Switzerland)
- Abbott Laboratories (U.S.)
- Zealand Pharma A/S (Denmark)
- Hanmi Pharm. Co., Ltd. (South Korea)
- OxThera (Sweden)
- AmeriPharma Specialty Care (U.S.)
- ContinuumRx (U.S.)
- Napo Therapeutics (Switzerland)
- Eclipse Regenesis (U.S.)
- AcuLife Healthcare Private Limited (India)
- Ferring Pharmaceuticals (Switzerland)
- Shandong Qidu Pharmaceutical Co., Ltd. (China)
- Choice Parenteral Nutrition LLC (U.S.)
- Integrated Care Systems (U.S.)
- Beverly Hills Digestive Care (U.S.)
- Stanford Health Care (U.S.)
- Vision Parenteral (U.S.)
- Amsino International, Inc. (U.S.)
- Aculife Healthcare (India)
- Nutrego (Netherlands)
- Camvitaa (India)
- Laboratoire Dielen (France)
- Infusion Solutions (U.S.)
- Aurora Health Care (U.S.)
Latest Developments in North America Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market
- In 2026, Takeda Pharmaceutical Company Limited continued expanding its gastrointestinal disease and rare disorder therapeutic portfolio through investments in biologics, gastrointestinal innovation, and advanced intestinal disorder treatment research, reinforcing its long-term strategic position in the North America Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market.
- In 2026, Abbott Laboratories continued focusing on advanced clinical nutrition and gastrointestinal care solutions through ongoing innovation in specialized nutritional formulations and hospital-based nutrition support therapies, strengthening its position in the Global Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market.
- In March 2026, Nestlé Health Science introduced innovative medical nutrition solutions and strengthened its nutrition and health science integration strategy to expand its clinical nutrition and gastrointestinal health portfolio, supporting growth opportunities in the Global Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market. 2026, Unilever announced the acquisition of U.S.-based supplement brand Grüns to expand its wellness and health portfolio. This development strengthens Unilever’s position in the growing nutraceutical and cosmeceutical segments.
- In April 2026, Baxter International showcased recent innovations at the AORN Global Surgical Conference & Expo 2026 and continued expanding its nutritional care and connected healthcare technologies portfolio, reinforcing its presence in critical care and SBS-IF-related treatment solutions.
- In April 2026, Fresenius Kabi AG highlighted its expanding clinical nutrition and infusion therapy portfolio through continued investments in advanced healthcare technologies and biologic treatment solutions, strengthening its position in the Global Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 DBMR MARKET POSITION GRID
2.7 VENDOR SHARE ANALYSIS
2.8 MULTIVARIATE MODELING
2.9 PRODUCT TYPE TIMELINE CURVE
2.1 MARKET APPLICATION COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.1.1 INTRODUCTION
4.1.2 POLITICAL ANALYSIS
4.1.3 ECONOMIC ANALYSIS
4.1.4 SOCIAL ANALYSIS
4.1.5 TECHNOLOGICAL ANALYSIS
4.1.6 ENVIRONMENTAL ANALYSIS
4.1.7 LEGAL ANALYSIS
4.1.8 CONCLUSION
4.2 PORTER’S FIVE FORCES ANALYSIS
4.2.1 INTRODUCTION
4.2.2 INTENSITY OF COMPETITIVE RIVALRY (HIGH)
4.2.3 BARGAINING POWER OF BUYERS – HIGH
4.2.4 THREAT OF NEW ENTRANTS – MODERATE
4.2.5 THREAT OF SUBSTITUTE PRODUCTS – MODERATE
4.2.6 BARGAINING POWER OF SUPPLIERS – MODERATE
4.2.7 CONCLUSION
4.3 COMPANY EVALUATION QUADRANT
4.4 PATIENT FUNNEL METHODOLOGY (MANDATORY MODEL)
4.4.1 A BOTTOM-UP PATIENT FUNNEL WILL BE CONSTRUCTED
4.4.1.1 TOTAL SBS POPULATION
4.4.1.2 SBS-IF POPULATION
4.4.1.3 DIAGNOSED SBS-IF PATIENTS
4.4.1.4 TREATED SBS-IF PATIENTS
4.4.1.5 THERAPY-SPECIFIC PATIENT POOLS
4.4.1.6 THIS ENSURES PATIENT NUMBERS ARE DIRECTLY ESTIMATED, NOT INFERRED FROM MARKET SIZE
4.4.1.7 NORTH AMERICA PATIENT FUNNEL SEGMENTATION
4.4.1.8 TOTAL SBS POPULATION
4.4.1.9 ADULT SBS
4.4.1.10 PEDIATRIC SBS
4.4.1.11 SBS-IF POPULATION
4.4.1.12 TYPE 1 SBS-IF (ACUTE)
4.4.1.13 TYPE 2 SBS-IF (PROLONGED ACUTE)
4.4.1.14 TYPE 3 SBS-IF (CHRONIC)
4.4.1.15 DIAGNOSED PATIENT POPULATION
4.4.1.16 DIAGNOSED – HOSPITAL-BASED
4.4.1.17 DIAGNOSED – OUTPATIENT FOLLOW-UP
4.4.1.18 UNDIAGNOSED / MISCLASSIFIED
4.4.1.19 TREATED PATIENT POPULATION
4.4.1.20 ACTIVELY TREATED PATIENTS
4.4.1.21 UNTREATED / SUPPORTIVE-ONLY
4.4.2 TREATMENT-SPECIFIC PATIENT SEGMENTATION (CRITICAL)
4.4.2.1 PN-DEPENDENT PATIENT POPULATION (CORE SEGMENT)
4.4.2.2 FULLY PN-DEPENDENT
4.4.2.3 PARTIALLY PN-DEPENDENT
4.4.2.4 ICU PN-DEPENDENT (TYPE 1 ACUTE)
4.4.2.5 HOME PN-DEPENDENT
4.4.2.6 GLP-2 ANALOGUE TREATED PATIENTS
4.4.2.7 INCLUDES PATIENTS RECEIVING TEDUGLUTIDE
4.4.2.8 PIPELINE THERAPIES (E.G., APRAGLUTIDE)
4.4.2.9 SUB-SEGMENTATION
4.4.2.10 PN-DEPENDENT RECEIVING GLP-2
4.4.2.11 PN-WEANING PATIENTS
4.4.2.12 PEDIATRIC VS ADULT
4.4.2.13 SUPPORTIVE PHARMACOTHERAPY PATIENTS (ATTRIBUTABLE)
4.4.2.14 ANTI-DIARRHEAL USERS
4.4.2.15 PPI USERS
4.4.2.16 ANTIBIOTIC (SIBO) PATIENTS
4.4.2.17 MICRONUTRIENT-DEPENDENT PATIENTS
4.4.2.18 SURGICAL & TRANSPLANT PATIENTS
4.4.2.19 INTESTINAL LENGTHENING PROCEDURES
4.4.2.20 TRANSPLANT PATIENTS
4.4.2.21 POST-TRANSPLANT SURVIVORS
4.4.3 PATIENT SEGMENTATION BY DEPENDENCY STATUS (HIGHLY IMPORTANT)
4.4.3.1 PN-DEPENDENT POPULATION
4.4.3.2 CORE REVENUE-DRIVING SEGMENT
4.4.3.3 PN-WEANING POPULATION
4.4.3.4 GLP-2 RESPONDERS
4.4.3.5 PN-INDEPENDENT POPULATION
4.4.3.6 MAINTAINED ON ORAL/ENTERAL THERAPY
4.4.4 PATIENT SEGMENTATION BY DISEASE PHASE (TYPE 1 FOCUS)
4.4.4.1 ACUTE PHASE (TYPE 1 SBS-IF)
4.4.4.2 ICU-MANAGED PATIENTS
4.4.4.3 HIGH PN UTILIZATION
4.4.4.4 ADAPTATION PHASE
4.4.4.5 TRANSITION TO ENTERAL NUTRITION
4.4.4.6 INITIATION OF GLP-2 THERAPY
4.4.4.7 RECOVERY / STABILIZATION PHASE
4.4.4.8 REDUCED PN DEPENDENCY
4.4.4.9 LONG-TERM MAINTENANCE
4.4.4.10 PATIENT SEGMENTATION BY CARE SETTING
4.4.4.11 HOSPITAL-BASED PATIENTS
4.4.4.12 ICU
4.4.4.13 SURGICAL WARDS
4.4.4.14 HOME CARE PATIENTS
4.4.4.15 HOME PARENTERAL NUTRITION (HPN)
4.4.4.16 SPECIALTY CENTERS
4.4.4.17 INTESTINAL REHABILITATION CENTERS
4.4.5 PATIENT SEGMENTATION BY DEMOGRAPHICS
4.4.5.1 AGE GROUP
4.4.5.2 NEONATES
4.4.5.3 PEDIATRIC
4.4.5.4 ADULTS
4.4.5.5 GERIATRIC
4.4.5.6 GENDER
4.4.5.7 MALE
4.4.5.8 FEMALE
4.4.6 PATIENT SEGMENTATION BY ETIOLOGY
4.4.6.1 ADULT ETIOLOGY
4.4.6.2 CROHN'S DISEASE
4.4.6.3 MESENTERIC ISCHEMIA
4.4.6.4 SURGICAL RESECTIONS
4.4.6.5 ONCOLOGY-RELATED
4.4.6.6 PEDIATRIC ETIOLOGY
4.4.6.7 NECROTIZING ENTEROCOLITIS (NEC)
4.4.6.8 CONGENITAL DEFECTS (ATRESIA, GASTROSCHISIS)
4.4.7 GEOGRAPHIC PATIENT DISTRIBUTION
4.4.7.1 NORTH AMERICA
4.4.7.2 U.S.
4.4.7.3 CANADA
4.4.7.4 EUROPE
4.4.7.5 GERMANY
4.4.7.6 FRANCE
4.4.7.7 UK
4.4.7.8 ITALY
4.4.7.9 SPAIN
4.4.7.10 ASIA-PAIFIC
4.4.7.11 JAPAN
4.4.7.12 CHINA
4.4.7.13 INDIA
4.4.8 TREATMENT PENETRATION & UTILIZATION RATES
4.4.8.1 PN PENETRATION RATE
4.4.8.2 % OF SBS-IF PATIENTS ON PN
4.4.8.3 GLP-2 PENETRATION RATE
4.4.8.4 % OF ELIGIBLE PATIENTS RECEIVING GLP-2
4.4.8.5 SUPPORTIVE THERAPY PENETRATION
4.4.8.6 ANTI-DIARRHEAL USAGE RATE
4.4.8.7 PPI USAGE RATE
4.4.8.8 PATIENT-LEVEL COST MODELING
4.4.8.9 ANNUAL COST PER PATIENT
4.4.8.10 PN COST (HOSPITAL VS HOME)
4.4.8.11 GLP-2 THERAPY COST
4.4.8.12 SUPPORTIVE THERAPY COST
4.4.9 COST BY PATIENT TYPE
4.4.9.1 PN-DEPENDENT
4.4.9.2 GLP-2 TREATED
4.4.9.3 TRANSPLANT
4.4.9.4 OUTPUT DELIVERABLES (EXCEL – CLIENT CRITICAL)
4.4.9.5 TOTAL SBS-IF PATIENTS (BY COUNTRY)
4.4.9.6 DIAGNOSED VS TREATED PATIENTS
4.4.9.7 PN-DEPENDENT PATIENTS
4.4.9.8 GLP-2 TREATED PATIENTS
4.4.9.9 TREATMENT PENETRATION RATES
4.4.9.10 AVERAGE ANNUAL COST PER THERAPY
4.5 INDUSTRY INSIGHTS
4.5.1 INTRODUCTION
4.5.2 INDUSTRY STRUCTURE OVERVIEW
4.5.3 MICRO AND MACRO ECONOMIC FACTORS
4.5.4 PENETRATION AND GROWTH PROSPECT MAPPING
4.5.5 KEY PRICING STRATEGIES
4.5.6 INTERVIEWS WITH SPECIALISTS
4.5.7 ANALYSIS AND RECOMMENDATION
4.5.8 CONCLUSION
4.6 WAR-DRIVEN DISRUPTION IN PHARMACEUTICAL SUPPLY CHAINS, GEOGRAPHIC FOOTPRINTS, STRUCTURAL CHANGES, AND ADAPTIVE STRATEGIES
4.6.1 INTRODUCTION
4.6.2 SUPPLY CHAIN RESILIENCE
4.6.2.1 DIVERSIFICATION OF INGREDIENT AND PN/DRUG SUPPLIERS
4.6.2.2 ESTABLISHMENT OF REGIONAL PRODUCTION HUBS
4.6.2.3 STRATEGIC STOCKPILING OF CRITICAL PN BAGS, GLP-2 ANALOGUES, AND MEDICAL DEVICES
4.6.2.4 DEVELOPMENT OF ALTERNATIVE LOGISTICS AND COLD CHAIN ROUTES
4.6.2.5 STRATEGIC PARTNERSHIPS WITH LEADING CDMOS (E.G., CATALENT, LONZA)
4.6.2.6 EXPANSION OF MANUFACTURING, FILL-FINISH, AND PACKAGING CAPABILITIES FOR PN & GLP-2
4.6.3 ENERGY & MANUFACTURING OPERATIONAL COST RISK
4.6.3.1 RISING ENERGY COSTS IN PARENTERAL NUTRITION & DRUG FACILITIES
4.6.3.2 INCREASED COSTS FOR RAW MATERIALS, LIPID EMULSIONS, AND PHARMACEUTICALS
4.6.3.3 LONG-TERM ENERGY PROCUREMENT STRATEGIES FOR PN MANUFACTURERS
4.6.3.4 ADOPTION OF ENERGY-EFFICIENT MANUFACTURING TECHNOLOGIES
4.6.3.5 DEPLOYMENT OF ADVANCED AUTOMATION AND CONTINUOUS SYSTEMS
4.6.3.6 INTEGRATION OF RENEWABLE ENERGY IN MANUFACTURING FACILITIES
4.6.4 GEOGRAPHIC FOOTPRINT REASSESSMENT
4.6.4.1 EXPANSION OF MANUFACTURING IN STABLE REGIONS
4.6.4.2 DIVERSIFICATION OF NORTH AMERICA PN/GLP-2 PRODUCTION SITES
4.6.4.3 RELOCATION OF KEY INPUT/INTERMEDIATE PRODUCTION
4.6.4.4 EXPANSION INTO EMERGING MARKETS WITH HIGH SBS-IF BURDEN
4.6.4.5 ESTABLISHMENT OF REGIONAL COLD CHAIN TRANSIT AND DISTRIBUTION HUBS
4.6.5 SCENARIO PLANNING & RISK MANAGEMENT
4.6.5.1 DEVELOPMENT OF SUPPLY CHAIN CONTINGENCY PLANS
4.6.5.2 MULTI-SOURCE PROCUREMENT STRATEGIES FOR PN/GLP-2
4.6.5.3 GOVERNMENT AND HEALTH AUTHORITY COLLABORATIONS
4.6.5.4 CRISIS-RESPONSE SUPPLY NETWORKS FOR CRITICAL THERAPIES
4.6.5.5 DEPLOYMENT OF PREDICTIVE SUPPLY CHAIN ANALYTICS IN SBS-IF MARKET
4.6.6 CASH & FINANCIAL PROTECTION
4.6.7 STRENGTHENING CAPITAL RESERVES FOR PN & BIOPHARMA EXPANSION
4.6.7.1 DIVERSIFICATION OF PRODUCT PORTFOLIOS AND REVENUE STREAMS
4.6.7.2 INVESTMENTS IN DOMESTIC PRODUCTION INFRASTRUCTURE
4.6.7.3 GOVERNMENT INCENTIVES AND PUBLIC-PRIVATE PARTNERSHIPS
4.6.7.4 LONG-TERM PROCUREMENT CONTRACTS WITH HEALTHCARE SYSTEMS
4.6.8 DATA PROTECTION
4.6.8.1 DATA PROTECTION FRAMEWORKS FOR CLINICAL AND REAL-WORLD SBS-IF DATA
4.6.8.2 PROTECTION OF CLINICAL TRIAL DATA, PATIENT DATA, AND DRUG DEVELOPMENT
4.6.8.3 SECURE CLOUD INFRASTRUCTURE FOR SBS-IF DATA MANAGEMENT
4.6.8.4 AI-DRIVEN THREAT DETECTION IN MARKET RESEARCH AND PHARMA NETWORKS
4.6.8.5 COMPLIANCE WITH PHARMACEUTICAL DATA REGULATIONS & GXP
4.6.9 NEW BUSINESS AND EMERGING REVENUE OPPORTUNITIES & FUTURE OUTLOOK
4.6.10 CONCLUSION
4.7 EPIDEMIOLOGY
4.7.1 INTRODUCTION
4.7.2 INCIDENCE OF TYPE 1 SBS-IF BY GENDER
4.7.3 TREATMENT RATE
4.7.4 MORTALITY RATE
4.7.5 TREATMENT ADHERENCE AND SWITCH MODEL
4.7.6 PATIENT TREATMENT SUCCESS RATES
4.7.7 CONCLUSION
4.8 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE NORTH AMERICA TYPE 1 SBS-IF MARKET
4.9 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE – NORTH AMERICA TYPE 1 SBS-IF MARKET
4.1 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE – NORTH AMERICA TYPE 1 SBS-IF MARKET
4.11 PIPELINE ANALYSIS
4.11.1 INTRODUCTION
4.11.2 CLINICAL TRIALS AND PHASE ANALYSIS
4.11.3 DRUG & BIOTHERAPY PIPELINE
4.11.4 PHASE III CANDIDATES (E.G., APRAGLUTIDE)
4.11.5 PHASE II CANDIDATES (E.G., LONG-ACTING GLP-2)
4.11.6 PHASE I CANDIDATES (EMERGING REGENERATIVE/CELLULAR)
4.11.7 OTHERS (PRE-CLINICAL, EN FORMULATION PIPELINE)
4.11.8 CONCLUSION
4.12 PIPELINE ANALYSIS
4.12.1 INTRODUCTION
4.12.2 TAKEDA PHARMACEUTICAL COMPANY – R&D LEADERSHIP IN INTESTINAL REGENERATION THERAPIES
4.12.3 BAXTER INTERNATIONAL – PARENTERAL NUTRITION AND INFUSION SYSTEM INNOVATION
4.12.4 FRESENIUS KABI AG – CLINICAL NUTRITION AND INJECTABLE THERAPY DEVELOPMENT
4.12.5 NESTLÉ HEALTH SCIENCE – MEDICAL NUTRITION AND GUT ADAPTATION RESEARCH
4.12.6 ABBOTT LABORATORIES – INTEGRATED NUTRITION AND METABOLIC MONITORING SOLUTIONS
4.12.7 CONCLUSION
4.13 MARKETED THERAPY ANALYSIS
4.13.1 INTRODUCTION
4.13.2 DRUG/THERAPY
4.13.2.1 BRAND NAME
4.13.2.2 GENERICS NAME
4.13.3 PHARMACOLOGICAL CLASSIFICATION
4.13.4 PRIMARY INDICATION
4.13.5 MARKET STATUS
4.13.6 MEDICATION TYPE
4.13.7 DOSAGE FORM
4.13.8 DOSAGE AVAILABILITY
4.13.9 PACKAGING TYPE
4.13.10 ROUTE OF ADMINISTRATION
4.13.11 DOSING FREQUENCY
4.13.12 THERAPY INSIGHT
4.13.13 AN OVERVIEW OF DRUG DEVELOPMENT ACTIVITIES, REGULATORY MILESTONES, SAFETY/EFFICACY, MARKET EXCLUSIVITY DATA
4.13.14 FORECAST MARKET OUTLOOK
4.13.14.1 CROSS COMPETITION
4.13.14.2 THERAPEUTIC PORTFOLIO
4.13.14.3 CURRENT DEVELOPMENT SCENARIO
4.13.15 CONCLUSION
4.14 PIPELINE ANALYSIS - NORTH AMERICA TYPE 1 SBS-IF TREATMENT MARKET
4.14.1 CLINICAL TRIALS AND PHASE ANALYSIS
4.14.2 DRUG AND BIOTHERAPY PIPELINE
4.14.3 PHASE III CANDIDATES
4.14.4 PHASE II CANDIDATES
4.14.5 PHASE I CANDIDATES
4.14.6 OTHERS (PRE-CLINICAL AND RESEARCH STAGE)
4.15 R & D ANALYSIS
4.15.1 COMPARATIVE ANALYSIS
4.15.2 DEVELOPMENTAL LANDSCAPE
4.15.3 INSIGHTS ON REGULATORY MILESTONES
4.15.4 THERAPEUTIC ASSESSMENT
4.15.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
5 HEALTHCARE TARIFFS IMPACT ANALYSIS
5.1 OVERVIEW
5.2 TARIFF STRUCTURES
5.2.1 NORTH AMERICA VS. REGIONAL TARIFF STRUCTURES
5.2.2 UNITED STATES: MEDICARE/MEDICAID TARIFF POLICIES
5.2.3 ASIA-PACIFIC: GOVERNMENT TARIFFS ON IMPORTED PN/DRUG THERAPIES
5.2.4 EMERGING MARKETS: TARIFF CHALLENGES FOR NUTRITION & BIOLOGICS
5.2.5 MAJOR MARKET UPTAKE
5.3 PHARMACEUTICAL TARIFFS AND TRADE BARRIERS
5.3.1 IMPORT DUTIES ON PN KITS, GLP-2 VS. GENERICS
5.3.2 IMPACT ON AFFORDABILITY & ACCESS
5.3.3 KEY TRADE AGREEMENTS AFFECTING SBS-IF PRODUCTS
5.4 IMPACT OF HEALTHCARE TARIFFS ON PROVIDERS/PATIENTS
5.4.1 COST BURDEN ON HOSPITALS AND FACILITIES
5.4.2 EFFECT ON PATIENT AFFORDABILITY & INSURANCE COVERAGE
5.4.3 ROLE IN MEDICAL TOURISM FOR ADVANCED SBS-IF THERAPIES
5.5 TRADE AGREEMENTS AND HEALTHCARE TARIFFS
5.5.1 WTO REGULATIONS
5.5.2 TRADE WARS IMPACT ON SUPPLY CHAIN
5.5.3 FTAS IN REDUCING TARIFFS
5.6 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY
5.7 IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR
6 MARKET ACCESS
6.1 10-YEAR MARKET FORECAST
6.2 CLINICAL TRIAL RECENT UPDATES
6.3 ANNUAL NEW FDA APPROVALS FOR SBS-IF TREATMENTS
6.4 MANUFACTURERS, DISTRIBUTORS, AND DEALS
6.5 MAJOR MARKET UPTAKE
6.6 CURRENT TREATMENT PRACTICES
6.7 IMPACT OF UPCOMING THERAPIES
7 REGULATORY FRAMEWORK–
7.1 INTRODUCTION
7.2 REGULATORY APPROVAL PROCESS
7.3 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
7.4 REGULATORY APPROVAL PATHWAYS
7.5 LICENSING AND REGISTRATION
7.6 POST-MARKETING SURVEILLANCE
7.7 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
7.8 CONCLUSION
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 RISING SBS-IF PATIENT POPULATION
8.1.2 GROWING ADOPTION OF GLP-2 THERAPIES
8.1.3 INCREASING GOVERNMENT & ORPHAN DRUG SUPPORT
8.2 RESTRAINTS
8.2.1 HIGH COST OF SBS-IF TREATMENT
8.2.2 LIMITE.D AWARENESS & DELAYED DIAGNOSIS
8.3 OPPORTUNITIES
8.3.1 COMPLEX MULTIDISCIPLINARY PATIENT MANAGEMENT
8.3.2 STRINGENT REGULATORY APPROVAL PROCESSES
8.4 CHALLENGES
8.4.1 ADVANCEMENTS IN REGENERATIVE MEDICINE
8.4.2 EXPANSION OF HOME-BASED NUTRITIONAL CARE
9 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY
9.1 OVERVIEW
9.2 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)
9.2.1 NUTRITIONAL SUPPORT THERAPY
9.2.2 PHARMACOLOGICAL THERAPY
9.2.3 SURGICAL & INTERVENTIONAL TREATMENT
9.2.4 EMERGING & ADVANCED THERAPIES
9.3 NORTH AMERICA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.3.1 PARENTERAL NUTRITION (PN)
9.3.2 ENTERAL NUTRITION (EN)
9.3.3 PN COMPOSITION
9.4 NORTH AMERICA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.4.1 HOME PARENTERAL NUTRITION (HPN)
9.4.2 PERIPHERAL PARENTERAL NUTRITION (PPN)
9.4.3 CYCLIC PARENTERAL NUTRITION
9.5 NORTH AMERICA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.5.1 HOSPITAL-BASED TPN
9.5.2 ICU-BASED TPN
9.6 NORTH AMERICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
9.6.1 ADULT HPN
9.6.2 PEDIATRIC HPN
9.7 NORTH AMERICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)
9.7.1 LONG-TERM HPN
9.7.2 SHORT-TERM HPN
9.8 NORTH AMERICA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.8.1 ORAL FEEDING
9.8.2 TUBE FEEDING
9.8.3 FORMULA TYPE
9.9 NORTH AMERICA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.9.1 NASOGASTRIC (NG)
9.9.2 PEG FEEDING
9.9.3 JEJUNOSTOMY FEEDING
9.1 NORTH AMERICA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.10.1 POLYMERIC
9.10.2 ELEMENTAL
9.10.3 SEMI-ELEMENTAL
9.11 NORTH AMERICA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.11.1 MACRONUTRIENTS
9.11.2 ELECTROLYTES & FLUIDS
9.11.3 MICRONUTRIENTS
9.12 NORTH AMERICA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.12.1 AMINO ACIDS
9.12.2 LIPID EMULSIONS
9.12.3 DEXTROSE
9.13 NORTH AMERICA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.13.1 VITAMINS
9.13.2 TRACE ELEMENTS
9.14 NORTH AMERICA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
9.14.1 NORTH AMERICA
9.14.2 EUROPE
9.14.3 ASIA-PACIFIC
9.14.4 MIDDLE EAST AND AFRICA
9.14.5 SOUTH AMERICA
9.15 NORTH AMERICA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.15.1 HORMONAL & INTESTINAL ADAPTATION THERAPY
9.15.2 ANTI-DIARRHEAL THERAPY
9.15.3 ANTI-SECRETORY THERAPY
9.15.4 MICRONUTRIENT SUPPLEMENTATION
9.15.5 ANTI-INFECTIVE THERAPY
9.15.6 BILE ACID & ABSORPTION MODIFIERS
9.16 NORTH AMERICA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.16.1 GLP-2 ANALOGUES
9.16.2 GROWTH HORMONE THERAPY
9.16.3 IGF-1 & ANALOGUES
9.17 NORTH AMERICA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.17.1 TEDUGLUTIDE
9.17.2 APRAGLUTIDE (LATE-STAGE)
9.17.3 LONG-ACTING GLP-2 ANALOGUES
9.18 NORTH AMERICA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)
9.18.1 HUMATROPE
9.18.2 NORDITROPIN
9.18.3 GENOTROPIN
9.19 NORTH AMERICA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.19.1 INCRELEX
9.19.2 OTHERS
9.2 NORTH AMERICA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.20.1 OPIOID-BASED
9.20.2 NON-OPIOID AGENTS
9.21 NORTH AMERICA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.21.1 LOPERAMIDE
9.21.2 CODEINE
9.22 NORTH AMERICA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.22.1 PROTON PUMP INHIBITORS
9.22.2 SOMATOSTATIN ANALOGUES
9.22.3 H2 RECEPTOR ANTAGONISTS
9.23 NORTH AMERICA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.23.1 OMEPRAZOLE
9.23.2 PANTOPRAZOLE
9.23.3 ESOMEPRAZOLE
9.23.4 OTHERS
9.24 NORTH AMERICA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)
9.24.1 OCTREOTIDE
9.24.2 OTHERS
9.25 NORTH AMERICA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.25.1 FAMOTIDINE
9.25.2 OTHERS
9.26 NORTH AMERICA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.26.1 FAT-SOLUBLE VITAMINS (A, D, E, K)
9.26.2 ELECTROLYTES
9.26.3 VITAMIN B12
9.26.4 MINERAL SUPPLEMENTATION
9.27 NORTH AMERICA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.27.1 BROAD-SPECTRUM ANTIBIOTICS
9.27.2 SIBO-TARGETED THERAPY
9.28 NORTH AMERICA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.28.1 BILE ACID SEQUESTRANTS
9.28.2 FAT ABSORPTION ENHANCERS
9.29 NORTH AMERICA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.29.1 CHOLESTYRAMINE
9.29.2 COLESEVELAM
9.29.3 OTHERS
9.3 NORTH AMERICA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
9.30.1 NORTH AMERICA
9.30.2 EUROPE
9.30.3 ASIA-PACIFIC
9.30.4 MIDDLE EAST AND AFRICA
9.30.5 SOUTH AMERICA
9.31 NORTH AMERICA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.31.1 INTESTINAL LENGTHENING PROCEDURES
9.31.2 OSTOMY & RECONSTRUCTION
9.31.3 INTESTINAL TRANSPLANTATION
9.32 NORTH AMERICA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.32.1 STEP PROCEDURE
9.32.2 BIANCHI PROCEDURE
9.33 NORTH AMERICA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.33.1 ILEOSTOMY
9.33.2 JEJUNOSTOMY
9.33.3 REVERSAL SURGERY
9.34 NORTH AMERICA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.34.1 ISOLATED SMALL BOWEL
9.34.2 LIVER + INTESTINE
9.34.3 MULTIVISCERAL TRANSPLANT
9.35 NORTH AMERICA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
9.35.1 NORTH AMERICA
9.35.2 EUROPE
9.35.3 ASIA-PACIFIC
9.35.4 MIDDLE EAST AND AFRICA
9.35.5 SOUTH AMERICA
9.36 NORTH AMERICA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.36.1 REGENERATIVE MEDICINE
9.36.2 MICROBIOME-BASED THERAPY
9.36.3 GENE THERAPY
9.37 NORTH AMERICA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.37.1 STEM CELL THERAPY
9.37.2 TISSUE-ENGINEERED INTESTINE
9.38 NORTH AMERICA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.38.1 PROBIOTICS
9.38.2 FMT
9.39 NORTH AMERICA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.39.1 ABSORPTIVE FUNCTION TARGETING
9.39.2 MUCOSAL GROWTH MODULATION
9.4 NORTH AMERICA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
9.40.1 NORTH AMERICA
9.40.2 EUROPE
9.40.3 ASIA-PACIFIC
9.40.4 MIDDLE EAST AND AFRICA
9.40.5 SOUTH AMERICA
10 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION
10.1 OVERVIEW
10.2 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)
10.2.1 CORE SBS-IF MARKET
10.2.2 SBS-IF ATTRIBUTABLE MARKET
10.2.3 ADJACENT / NON-SPECIFIC MARKET
10.3 NORTH AMERICA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
10.3.1 PARENTERAL NUTRITION
10.3.2 GLP-2 ANALOGUES
10.4 NORTH AMERICA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
10.4.1 NORTH AMERICA
10.4.2 EUROPE
10.4.3 ASIA-PACIFIC
10.4.4 MIDDLE EAST AND AFRICA
10.4.5 SOUTH AMERICA
10.5 NORTH AMERICA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
10.5.1 ANTI-DIARRHEALS
10.5.2 PPIS
10.5.3 ANTIBIOTICS
10.6 NORTH AMERICA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
10.6.1 NORTH AMERICA
10.6.2 EUROPE
10.6.3 ASIA-PACIFIC
10.6.4 MIDDLE EAST AND AFRICA
10.6.5 SOUTH AMERICA
10.7 NORTH AMERICA ADJACENT / NON-SPECIFIC MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
10.7.1 NORTH AMERICA
10.7.2 EUROPE
10.7.3 ASIA-PACIFIC
10.7.4 MIDDLE EAST AND AFRICA
10.7.5 SOUTH AMERICA
11 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE
11.1 OVERVIEW
11.2 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)
11.2.1 ACUTE PHASE (TYPE 1 SBS-IF)
11.2.2 ADAPTATION PHASE
11.2.3 RECOVERY PHASE
11.3 NORTH AMERICA ACUTE PHASE (TYPE 1 SBS-IF) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
11.3.1 NORTH AMERICA
11.3.2 EUROPE
11.3.3 ASIA-PACIFIC
11.3.4 MIDDLE EAST AND AFRICA
11.3.5 SOUTH AMERICA
11.4 NORTH AMERICA ADAPTATION PHASE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
11.4.1 NORTH AMERICA
11.4.2 EUROPE
11.4.3 ASIA-PACIFIC
11.4.4 MIDDLE EAST AND AFRICA
11.4.5 SOUTH AMERICA
11.5 NORTH AMERICA RECOVERY PHASE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
11.5.1 NORTH AMERICA
11.5.2 EUROPE
11.5.3 ASIA-PACIFIC
11.5.4 MIDDLE EAST AND AFRICA
11.5.5 SOUTH AMERICA
12 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE
12.1 OVERVIEW
12.2 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
12.2.1 ADULT
12.2.2 PEDIATRIC
12.3 NORTH AMERICA ADULT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
12.3.1 NORTH AMERICA
12.3.2 EUROPE
12.3.3 ASIA-PACIFIC
12.3.4 MIDDLE EAST AND AFRICA
12.3.5 SOUTH AMERICA
12.4 NORTH AMERICA PEDIATRIC IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
12.4.1 NORTH AMERICA
12.4.2 EUROPE
12.4.3 ASIA-PACIFIC
12.4.4 MIDDLE EAST AND AFRICA
12.4.5 SOUTH AMERICA
13 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
13.2.1 INTRAVENOUS
13.2.2 SUBCUTANEOUS
13.2.3 ORAL
13.2.4 ENTERAL
13.3 NORTH AMERICA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
13.3.1 PN
13.3.2 INJECTABLES
13.4 NORTH AMERICA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
13.4.1 NORTH AMERICA
13.4.2 EUROPE
13.4.3 ASIA-PACIFIC
13.4.4 MIDDLE EAST AND AFRICA
13.4.5 SOUTH AMERICA
13.5 NORTH AMERICA SUBCUTANEOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
13.5.1 NORTH AMERICA
13.5.2 EUROPE
13.5.3 ASIA-PACIFIC
13.5.4 MIDDLE EAST AND AFRICA
13.5.5 SOUTH AMERICA
13.6 NORTH AMERICA ORAL IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
13.6.1 NORTH AMERICA
13.6.2 EUROPE
13.6.3 ASIA-PACIFIC
13.6.4 MIDDLE EAST AND AFRICA
13.6.5 SOUTH AMERICA
13.7 NORTH AMERICA ENTERAL IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
13.7.1 NORTH AMERICA
13.7.2 EUROPE
13.7.3 ASIA-PACIFIC
13.7.4 MIDDLE EAST AND AFRICA
13.7.5 SOUTH AMERICA
14 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER
14.1 OVERVIEW
14.2 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)
14.2.1 HOSPITALS (ACUTE CARE)
14.2.2 HOME CARE (HPN PROGRAMS)
14.2.3 ICU SETTINGS
14.2.4 PECIALTY GI CENTERS
14.2.5 PEDIATRIC SPECIALTY HOSPITALS
14.3 NORTH AMERICA HOSPITALS (ACUTE CARE) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
14.3.1 NORTH AMERICA
14.3.2 EUROPE
14.3.3 ASIA-PACIFIC
14.3.4 MIDDLE EAST AND AFRICA
14.3.5 SOUTH AMERICA
14.4 NORTH AMERICA HOME CARE (HPN PROGRAMS) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
14.4.1 NORTH AMERICA
14.4.2 EUROPE
14.4.3 ASIA-PACIFIC
14.4.4 MIDDLE EAST AND AFRICA
14.4.5 SOUTH AMERICA
14.5 NORTH AMERICA ICU SETTINGS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
14.5.1 NORTH AMERICA
14.5.2 EUROPE
14.5.3 ASIA-PACIFIC
14.5.4 MIDDLE EAST AND AFRICA
14.5.5 SOUTH AMERICA
14.6 NORTH AMERICA SPECIALTY GI CENTERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
14.6.1 NORTH AMERICA
14.6.2 EUROPE
14.6.3 ASIA-PACIFIC
14.6.4 MIDDLE EAST AND AFRICA
14.6.5 SOUTH AMERICA
14.7 NORTH AMERICA PEDIATRIC SPECIALTY HOSPITALS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
14.7.1 NORTH AMERICA
14.7.2 EUROPE
14.7.3 ASIA-PACIFIC
14.7.4 MIDDLE EAST AND AFRICA
14.7.5 SOUTH AMERICA
15 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
15.2.1 HOSPITAL PHARMACY
15.2.2 SPECIALTY PHARMACY
15.2.3 RETAIL PHARMACY
15.2.4 ONLINE PHARMACY
15.3 NORTH AMERICA HOSPITAL PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
15.3.1 NORTH AMERICA
15.3.2 EUROPE
15.3.3 ASIA-PACIFIC
15.3.4 MIDDLE EAST AND AFRICA
15.3.5 SOUTH AMERICA
15.4 NORTH AMERICA SPECIALTY PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
15.4.1 NORTH AMERICA
15.4.2 EUROPE
15.4.3 ASIA-PACIFIC
15.4.4 MIDDLE EAST AND AFRICA
15.4.5 SOUTH AMERICA
15.5 NORTH AMERICA RETAIL PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
15.5.1 NORTH AMERICA
15.5.2 EUROPE
15.5.3 ASIA-PACIFIC
15.5.4 MIDDLE EAST AND AFRICA
15.5.5 SOUTH AMERICA
16 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION
16.1 NORTH AMERICA
16.1.1 U.S.
16.1.2 CANADA
16.1.3 MEXICO
17 NORTH AMERICA NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: COMPANY LANDSCAPE
17.1 MANUFACTURER COMPANY SHARE ANALYSIS: GLOBAL
18 SWOT ANALYSIS
19 COMPANY PROFILES
19.1 FRESENIUS KABI
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENT
19.2 BAXTER INTERNATIONAL INC.
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENT
19.3 NESTLÉ HEALTH SCIENCE
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 ABBOTT LABORATORIES
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENT
19.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENT
19.6 MOOG COMPANY
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT/NEWS
19.7 ACULIFE HEALTHCARE
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENT
19.8 AMSINO INTERNATIONAL, INC
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENT
19.9 AURORA HEALTH CARE
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENT
19.1 AMERIPHARMA SPECIALTY CARE.
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENT
19.11 BAUSCH HEALTH COMPANIES INC
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENT
19.12 BEVELRYHILLS DIGESTIVE CARE
19.12.1 COMPANY SNAPSHOT
19.12.2 PRODUCT PORTFOLIO
19.12.3 RECENT DEVELOPMENT
19.13 B. BRAUN SE
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENT
19.14 CAMVITTA
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENT
19.15 CHOICE PARENTERAL NUTRITION LLC
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENT
19.16 CONTINUUMRX
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENT
19.17 FERRING PHARMACEUTICALS
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENT
19.18 GRIFOLS S.A.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENT
19.19 HIKMA PHARMACEUTICALS
19.19.1 COMPANY SNAPSHOT
19.19.2 REVENUE ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENT
19.2 HOSPIRA (PART OF PFIZER INC.)
19.20.1 COMPANY SNAPSHOT
19.20.2 REVENUE ANALYSIS
19.20.3 PRODUCT PORTFOLIO
19.20.4 RECENT DEVELOPMENT
19.21 HANMI PHARM.CO.,LTD.
19.21.1 COMPANY SNAPSHOT
19.21.2 REVENUE ANALYSIS
19.21.3 PRODUCT PORTFOLIO
19.21.4 RECENT DEVELOPMENT
19.22 ICU MEDICAL, INC.
19.22.1 COMPANY SNAPSHOT
19.22.2 REVENUE ANALYSIS
19.22.3 PRODUCT PORTFOLIO
19.22.4 RECENT DEVELOPMENT
19.23 INFUSION SOLUTIONS
19.23.1 COMPANY SNAPSHOT
19.23.2 PRODUCT PORTFOLIO
19.23.3 RECENT DEVELOPMENT
19.24 INTEGRATED CARE SYSTEMS
19.24.1 COMPANY SNAPSHOT
19.24.2 PRODUCT PORTFOLIO
19.24.3 RECENT DEVELOPMENT
19.25 JEDUX PARENTERAL PRIVATE LIMITED
19.25.1 COMPANY SNAPSHOT
19.25.2 PRODUCT PORTFOLIO
19.25.3 RECENT DEVELOPMENT
19.26 LABORATOIRE DIELEN
19.26.1 COMPANY SNAPSHOT
19.26.2 PRODUCT PORTFOLIO
19.26.3 RECENT DEVELOPMENT
19.27 NAPO THERAPEUTICS.
19.27.1 COMPANY SNAPSHOT
19.27.2 PRODUCT PORTFOLIO
19.27.3 RECENT DEVELOPMENT/NEWS
19.28 NUTREGO
19.28.1 COMPANY SNAPSHOT
19.28.2 PRODUCT PORTFOLIO
19.28.3 RECENT DEVELOPMENT
19.29 NUTRICIA (DANONE GROUP)
19.29.1 COMPANY SNAPSHOT
19.29.2 REVENUE ANALYSIS
19.29.3 PRODUCT PORTFOLIO
19.29.4 RECENT DEVELOPMENT
19.3 NUTRICIA NORTH AMERICA
19.30.1 COMPANY SNAPSHOTS
19.30.2 PRODUCT PORTFOLIO
19.30.3 RECENT DEVELOPMENT
19.31 NUTRISHARE
19.31.1 COMPANY SNAPSHOT
19.31.2 PRODUCT PORTFOLIO
19.31.3 RECENT DEVELOPMENT
19.32 OXTHERA
19.32.1 COMPANY SNAPSHOT
19.32.2 PRODUCT PORTFOLIO
19.32.3 RECENT DEVELOPMENT
19.33 PHARMKO, INC.
19.33.1 COMPANY SNAPSHOT
19.33.2 PRODUCT PORTFOLIO
19.33.3 RECENT DEVELOPMENT
19.34 PUERTO LIFE SCIENCES PVT. LTD.
19.34.1 COMPANY SNAPSHOT
19.34.2 PRODUCT PORTFOLIO
19.34.3 RECENT DEVELOPMENT
19.35 SHANDONG QIDU PHARMACEUTICAL CO., LTD.
19.35.1 COMPANY SNAPSHOT
19.35.2 PRODUCT PORTFOLIO
19.35.3 RECENT DEVELOPMENT
19.36 STANFORD HEALTH CARE
19.36.1 COMPANY SNAPSHOT
19.36.2 PRODUCT PORTFOLIO
19.36.3 RECENT DEVELOPMENT
19.37 UF HEALTH
19.37.1 COMPANY SNAPSHOT
19.37.2 PRODUCT PORTFOLIO
19.37.3 RECENT DEVELOPMENT
19.38 IRONWOOD PHARMACEUTICALS
19.38.1 COMPANY SNAPSHOT
19.38.2 REVENUE ANALYSIS
19.38.3 PRODUCT PORTFOLIO
19.38.4 RECENT DEVELOPMENT
19.39 VISION PARENTERAL
19.39.1 COMPANY SNAPSHOT
19.39.2 PRODUCT PORTFOLIO
19.39.3 RECENT DEVELOPMENT
19.4 ZEALAND PHARMA
19.40.1 COMPANY SNAPSHOT
19.40.2 REVENUE ANALYSIS
19.40.3 PRODUCT PORTFOLIO
19.40.4 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
List of Table
TABLE 1 TREATMENT RATE OF SBI-IF PATIENTS
TABLE 2 ESTIMATED THERAPY-SPECIFIC PATIENT POOLS
TABLE 3 ESTIMATED FUNNEL PATEGINTS
TABLE 4 KEY INDUSTRY INSIGHTS AND MARKET TRENDS IN THE NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET
TABLE 5 IMPACT OF WAR-DRIVEN DISRUPTIONS ON THE NORTH AMERICA TYPE 1 SBS-IF TREATMENT MARKET ECOSYSTEM AND INDUSTRY RESPONSE FRAMEWORK
TABLE 6 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE NORTH AMERICA TYPE 1 SBS-IF MARKET
TABLE 7 DISTRIBUTION OF OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE – NORTH AMERICA TYPE 1 SBS-IF MARKET
TABLE 8 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE – NORTH AMERICA TYPE 1 SBS-IF MARKET
TABLE 9 PIPELINE LANDSCAPE AND CLINICAL DEVELOPMENT OVERVIEW
TABLE 10 TOP ENTITIES BASED ON R&D GLANCE – NORTH AMERICA TYPE 1 SBS-IF TREATMENT MARKET
TABLE 11 PRECLINICAL / RESEARCH STAGE VACCINE CANDIDATES
TABLE 12 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)
TABLE 13 NORTH AMERICA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 14 NORTH AMERICA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 15 NORTH AMERICA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 16 NORTH AMERICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 17 NORTH AMERICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)
TABLE 18 NORTH AMERICA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 19 NORTH AMERICA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 20 NORTH AMERICA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 21 NORTH AMERICA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 22 NORTH AMERICA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 23 NORTH AMERICA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 24 NORTH AMERICA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 25 NORTH AMERICA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 26 NORTH AMERICA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 27 NORTH AMERICA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 28 NORTH AMERICA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)
TABLE 29 NORTH AMERICA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 30 NORTH AMERICA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 31 NORTH AMERICA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 32 NORTH AMERICA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 33 NORTH AMERICA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 34 NORTH AMERICA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)
TABLE 35 NORTH AMERICA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 36 NORTH AMERICA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 37 NORTH AMERICA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 38 NORTH AMERICA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 39 NORTH AMERICA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 40 NORTH AMERICA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 41 NORTH AMERICA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 42 NORTH AMERICA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 43 NORTH AMERICA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 44 NORTH AMERICA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 45 NORTH AMERICA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 46 NORTH AMERICA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 47 NORTH AMERICA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 48 NORTH AMERICA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 49 NORTH AMERICA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 50 NORTH AMERICA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 51 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)
TABLE 52 NORTH AMERICA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 53 NORTH AMERICA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 54 NORTH AMERICA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 55 NORTH AMERICA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 56 NORTH AMERICA ADJACENT / NON-SPECIFIC MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 57 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)
TABLE 58 NORTH AMERICA ACUTE PHASE (TYPE 1 SBS-IF) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 59 NORTH AMERICA ADAPTATION PHASE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 60 NORTH AMERICA RECOVERY PHASE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 61 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 62 NORTH AMERICA ADULT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 63 NORTH AMERICA PEDIATRIC IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 64 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
TABLE 65 NORTH AMERICA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 66 NORTH AMERICA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 67 NORTH AMERICA SUBCUTANEOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 68 NORTH AMERICA ORAL IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 69 NORTH AMERICA ENTERAL IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 70 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 71 NORTH AMERICA HOSPITALS (ACUTE CARE) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 72 NORTH AMERICA HOME CARE (HPN PROGRAMS) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 73 NORTH AMERICA ICU SETTINGS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 74 NORTH AMERICA SPECIALTY GI CENTERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 75 NORTH AMERICA PEDIATRIC SPECIALTY HOSPITALS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 76 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 77 NORTH AMERICA HOSPITAL PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 78 NORTH AMERICA SPECIALTY PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 79 NORTH AMERICA RETAIL PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 80 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, 2018-2033 (USD THOUSAND)
TABLE 81 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY COUNTRY, 2018-2033 (USD THOUSAND)
TABLE 82 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)
TABLE 83 NORTH AMERICA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 84 NORTH AMERICA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 85 NORTH AMERICA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 86 NORTH AMERICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 87 NORTH AMERICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)
TABLE 88 NORTH AMERICA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 89 NORTH AMERICA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 90 NORTH AMERICA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 91 NORTH AMERICA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 92 NORTH AMERICA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 93 NORTH AMERICA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 94 NORTH AMERICA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 95 NORTH AMERICA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 96 NORTH AMERICA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 97 NORTH AMERICA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)
TABLE 98 NORTH AMERICA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 99 NORTH AMERICA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 100 NORTH AMERICA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 101 NORTH AMERICA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 102 NORTH AMERICA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 103 NORTH AMERICA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)
TABLE 104 NORTH AMERICA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 105 NORTH AMERICA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 106 NORTH AMERICA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 107 NORTH AMERICA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 108 NORTH AMERICA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 109 NORTH AMERICA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 110 NORTH AMERICA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 111 NORTH AMERICA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 112 NORTH AMERICA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 113 NORTH AMERICA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 114 NORTH AMERICA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 115 NORTH AMERICA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 116 NORTH AMERICA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 117 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)
TABLE 118 NORTH AMERICA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 119 NORTH AMERICA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 120 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)
TABLE 121 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 122 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
TABLE 123 NORTH AMERICA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 124 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 125 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 126 US TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)
TABLE 127 US NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 128 US PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 129 US TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 130 US HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 131 US HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)
TABLE 132 US ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 133 US TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 134 US FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 135 US PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 136 US MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 137 US MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 138 US PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 139 US HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 140 US GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 141 US GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)
TABLE 142 US IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 143 US ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 144 US OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 145 US ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 146 US PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 147 US SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)
TABLE 148 US H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 149 US MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 150 US ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 151 US BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 152 US BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 153 US SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 154 US INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 155 US OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 156 US INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 157 US EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 158 US REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 159 US MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 160 US GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 161 US TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)
TABLE 162 US CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 163 US SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 164 US TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)
TABLE 165 US TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 166 US TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
TABLE 167 US INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 168 US TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 169 US TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 170 CANADA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)
TABLE 171 CANADA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 172 CANADA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 173 CANADA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 174 CANADA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 175 CANADA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)
TABLE 176 CANADA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 177 CANADA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 178 CANADA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 179 CANADA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 180 CANADA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 181 CANADA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 182 CANADA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 183 CANADA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 184 CANADA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 185 CANADA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)
TABLE 186 CANADA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 187 CANADA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 188 CANADA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 189 CANADA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 190 CANADA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 191 CANADA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)
TABLE 192 CANADA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 193 CANADA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 194 CANADA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 195 CANADA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 196 CANADA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 197 CANADA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 198 CANADA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 199 CANADA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 200 CANADA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 201 CANADA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 202 CANADA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 203 CANADA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 204 CANADA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 205 CANADA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)
TABLE 206 CANADA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 207 CANADA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 208 CANADA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)
TABLE 209 CANADA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 210 CANADA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
TABLE 211 CANADA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 212 CANADA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 213 CANADA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 214 MEXICO TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)
TABLE 215 MEXICO NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 216 MEXICO PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 217 MEXICO TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 218 MEXICO HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 219 MEXICO HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)
TABLE 220 MEXICO ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 221 MEXICO TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 222 MEXICO FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 223 MEXICO PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 224 MEXICO MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 225 MEXICO MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 226 MEXICO PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 227 MEXICO HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 228 MEXICO GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 229 MEXICO GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)
TABLE 230 MEXICO IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 231 MEXICO ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 232 MEXICO OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 233 MEXICO ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 234 MEXICO PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 235 MEXICO SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)
TABLE 236 MEXICO H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 237 MEXICO MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 238 MEXICO ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 239 MEXICO BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 240 MEXICO BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 241 MEXICO SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 242 MEXICO INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 243 MEXICO OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 244 MEXICO INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 245 MEXICO EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 246 MEXICO REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 247 MEXICO MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 248 MEXICO GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 249 MEXICO TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)
TABLE 250 MEXICO CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 251 MEXICO SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 252 MEXICO TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)
TABLE 253 MEXICO TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 254 MEXICO TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
TABLE 255 MEXICO INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 256 MEXICO TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 257 MEXICO TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
List of Figure
FIGURE 1 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: MULTIVARIVATE MODELING
FIGURE 10 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: PRODUCT TYPE TIMELINE CURVE
FIGURE 11 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: APPLICATION COVERAGE GRID
FIGURE 12 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: SEGMENTATION
FIGURE 13 FOUR SEGMENTS COMPRISE THE NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY (2025)
FIGURE 14 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: EXECUTIVE SUMMARY
FIGURE 15 RISING SBS-IF PATIENT POPULATION IS EXPECTED TO DRIVE THE NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET DURING THE FORECAST PERIOD OF 2026 TO 2033.
FIGURE 16 NUTRITIONAL SUPPORT THERAPY IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET IN 2026 & 2033
FIGURE 17 STRATEGIC DECISIONS
FIGURE 18 PESTEL ANALYSIS
FIGURE 19 DROC ANALYSIS
FIGURE 20 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY TREATMENT MODALITY, 2025
FIGURE 21 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY MARKET ATTRIBUTION, 2025
FIGURE 22 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY DISEASE MANAGEMENT PHASE, 2025
FIGURE 23 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY PATIENT TYPE, 2025
FIGURE 24 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2025
FIGURE 25 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY END USER, 2025
FIGURE 26 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2025
FIGURE 27 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: SNAPSHOT (2025)
FIGURE 28 NORTH AMERICA NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: COMPANY SHARE 2025 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
